SMCHD1 is a novel target for gene-activation therapy to treat Prader-Willi Syndrome
Preprint
Abstract
Prader-Willi Syndrome (PWS) is a neurodevelopmental disorder caused by lack of gene expression from the active paternal allele at an imprinted gene cluster on chromosome 15. Current treatments have limited efficacy as they target individual symptoms rather than the underlying cause of disease. All patients preserve a normal, yet epigenetically-silenced, copy of the PWS cluster genes; activation of this imprinted copy to restore necessary gene expression is an appealing option for tackling the root of the disorder. Here we have addressed the potential to activate these silent maternal genes by targeting the epigenetic regulator Structural Maintenance of Chromosomes Hinge domain containing 1 (SMCHD1). First, we expanded the role of SMCHD1 in repressing the PWS cluster from mice to humans, a critical step if SMCHD1 is to be a drug target. Second, we discovered that SMCHD1 represses the entire PWS locus in neural lineages, extending its previously known role at only half of the PWS genes. We show that deleting Smchd1 after early development in vivo is effective at causing PWS gene-activation in disease-relevant mouse tissues including hypothalamus, and that this has beneficial effects on phenotypes observed in a PWS mouse model. Despite SMCHD1 having a role in gene silencing elsewhere in the genome, our data suggest that targeting SMCHD1 after early development is remarkably safe. Taken together, these data propose SMCHD1 as a novel target for gene-activation therapy for PWS.Keywords
Funding Information
- National Health and Medical Research Council of Australia (1194345)
- National Health and Medical Research Council of Australia (2041117)
- National Health and Medical Research Council of Australia (2034104)
- National Health and Medical Research Council of Australia (2007996)
- Foundation for Prader Willi Research USA (825553)
- Prader Willi Research Foundation Australia
- Rebecca L. Cooper Medical Research Foundation (F20221078)
- Pamela and Lorenzo Galli Trust
- Brian M Davis Charitable Trust
- Walter and Eliza Hall Institute
- NHMRC IRIISS and Victorian State Government Operational Infrastructure Support
This publication has 78 references indexed in Scilit:
- Activation of the imprinted Prader-Willi syndrome locus by CRISPR-based epigenome editingCell Genomics, 2025
- Epigenetic modifier SMCHD1 maintains a normal pool of long-term hematopoietic stem cellsiScience, 2022
- Sleep disorders in Prader-Willi syndrome, evidence from animal models and humansSleep Medicine Reviews, 2021
- Optimizing Nervous System-Specific Gene Targeting with Cre Driver Lines: Prevalence of Germline Recombination and Influencing FactorsNeuron, 2020
- Smchd1 Targeting to the Inactive X Is Dependent on the Xist-HnrnpK-PRC1 PathwayCell Reports, 2018
- Schaaf‐Yang syndrome overview: Report of 78 individualsAmerican Journal of Medical Genetics Part A, 2018
- Sleep disordered breathing in patients with Prader-Willi syndrome: A multicenter studyPediatric Pulmonology, 2015
- Nutritional phases in Prader–Willi syndromeAmerican Journal of Medical Genetics Part A, 2011
- Mechanisms of imprinting of the Prader–Willi/Angelman regionAmerican Journal of Medical Genetics Part A, 2008
- Development of a SNP genotyping panel for genetic monitoring of the laboratory mouseGenomics, 2004